Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Jiangsu Hengrui Pharmaceuticals / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/jiangsu-hengrui-pharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:44224:1" rel="noopener">Jiangsu Hengrui Pharmaceuticals (1276 HK)</a> (JHP, <a href="https://www.smartkarma.com/entities/jiangsu-hengrui-medicine-co-ltd" target="_blank" data-smartkarma-citation="entities:14128:1" rel="noopener">600276 CH</a> ), a China-based pharmaceutical company, raised around US$1.5bn in its H-share listing.</li>
<li>JHP Has been ranked as one of the global Top 50 pharmaceutical companies by Pharm Exec for six consecutive years since 2019.</li>
<li>We have looked at the company’s past performance and other deal dynamics in our previous note. In this note, we talk about trading dynamics.</li>
</ul>



Jiangsu Hengrui Pharmaceuticals (1276 HK) (JHP, 600276 CH ), a China-based pharmaceutical company, raised around US$1.5bn in its H-share listing.
JHP Has been ranked as one of the global Top 50 pharmaceutical companies by Pharm Exec for six consecutive years since 2019.
We have looked at the company’s past performance and other deal dynamics in our previous note. In this note, we talk about trading dynamics.


Jiangsu Hengrui Pharma A/H Trading - Strong Demand for Quality Asset, but Is Pricey

Blue Lotus Non US Internet research, Blue Lotus Research Institute

Ying Pan

Blue Lotus Non US Internet research

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

Thematic (Sector/Industry)

<ul>
<li>NTES US/700 HK/002624 CH: NPPA released the May approval results for domestic and imported game code licenses（+/+/+）</li>
<li>NTES US: NetEase Games Conference Reveals Progress on 4 New Games (+)</li>
<li>BABA US/PDD US: EU Proposes EUR2 Fee on Cross-Border Small Parcels(-/-)</li>
</ul>


NTES US/700 HK/002624 CH: NPPA released the May approval results for domestic and imported game code licenses（+/+/+）
NTES US: NetEase Games Conference Reveals Progress on 4 New Games (+)
BABA US/PDD US: EU Proposes EUR2 Fee on Cross-Border Small Parcels(-/-)


[Blue Lotus Daily-TMT Update]:NTES US/700 HK/002624 CH/BABA US/PDD US/1357 HK

APAC IPOs & Placements, Aequitas Research

Nicholas Tan

APAC IPOs & Placements

<ul>
<li>
<a href="https://www.smartkarma.com/entities/xiamen-hithium" target="_blank" data-smartkarma-citation="entities:45043:1" rel="noopener">Xiamen Hithium (2190977D CH)</a>  is looking to raise at least US$500m in its upcoming HK IPO.</li>
<li>It is a leading global new energy technology company providing all-round energy storage solutions centred around energy storage batteries and systems.</li>
<li>In this note, we look at the firm's past performance.</li>
</ul>



Xiamen Hithium (2190977D CH)  is looking to raise at least US$500m in its upcoming HK IPO.
It is a leading global new energy technology company providing all-round energy storage solutions centred around energy storage batteries and systems.
In this note, we look at the firm's past performance.


Xiamen Hithium Pre-IPO: Potential Data Center Play

Asian Hedge Fund Manager, Long Short Equity, Macro

David Mudd

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/alibaba-pictures-group-ltd" target="_blank" data-smartkarma-citation="entities:20724:1" rel="noopener">Alibaba Pictures (1060 HK)</a> is expanding rapidly into complimentary areas such as online ticketing of cinema and live events with the recent acquisition of  Damai.cn from parent Alibaba.</li>
<li>
<a href="https://www.smartkarma.com/entities/alibaba-group-holding-ltd-d7b798e2-202d-4e01-9a1e-799e2ae8f0c7" target="_blank" data-smartkarma-citation="entities:28434:1" rel="noopener">Alibaba Group Holding (9988 HK)</a> is considering injecting other media platform assets like Youku  to realize synergies among its portfolio of companies.</li>
<li>Ali Pictures (Alipics) legacy film production business continues to expand globally with its American film production company, Amblin which is a partnership with Steven Spielberg.</li>
</ul>



Alibaba Pictures (1060 HK) is expanding rapidly into complimentary areas such as online ticketing of cinema and live events with the recent acquisition of  Damai.cn from parent Alibaba.

Alibaba Group Holding (9988 HK) is considering injecting other media platform assets like Youku  to realize synergies among its portfolio of companies.
Ali Pictures (Alipics) legacy film production business continues to expand globally with its American film production company, Amblin which is a partnership with Steven Spielberg.


BABA's Babies: They Are All Grown Up! Ali Pictures: A Blockbuster Company

Eastroc Beverage Group   / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/eastroc-beverage-group-co-ltd" target="_blank" data-smartkarma-citation="entities:34882:1" rel="noopener">Eastroc Beverage Group (605499 CH)</a> (EB), a China-based functional beverage company, aims to raise around US$1bn in its H-share listing.</li>
<li>According to Frost &amp; Sullivan (F&amp;S), EB has been the largest functional beverage company in China in terms of sales volume for four consecutive years since 2021.</li>
<li>In this note, we look at its past performance and other deal dynamics that might impact the listing.</li>
</ul>



Eastroc Beverage Group (605499 CH) (EB), a China-based functional beverage company, aims to raise around US$1bn in its H-share listing.
According to Frost &amp; Sullivan (F&amp;S), EB has been the largest functional beverage company in China in terms of sales volume for four consecutive years since 2021.
In this note, we look at its past performance and other deal dynamics that might impact the listing.


Eastroc Beverage A/H Listing - Energized - Fast Growth, Better Margins

China

Alibaba Group Holding Limited provides online sales services. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alibaba (BABA US)

Jiangsu Hengrui Pharma A/H Trading - Strong Demand for Quality Asset, but Is Pricey

Jiangsu Hengrui Pharmaceuticals (1276 HK) (JHP, 600276 CH ), a China-based pharmaceutical company, raised around US$1.5bn in its H-share listing....

Sumeet Singh

[Blue Lotus Daily-TMT Update]:NTES US/700 HK/002624 CH/BABA US/PDD US/1357 HK

NPPA releases May approval results for game licenses; NetEase Games Conference shows progress on 4 new games; EU proposes EUR2 fee on cross-border...

Blue Lotus Research Institute

Xiamen Hithium Pre-IPO: Potential Data Center Play

Xiamen Hithium (XH) is looking to raise at least US$500m in its upcoming HK IPO. It is a potential data-center growth play. In this note, we look...

Nicholas Tan

BABA's Babies: They Are All Grown Up! Ali Pictures: A Blockbuster Company

Ali Pictures reported results exceeding market expectations with growth in Revenue (+33%), Net profit(+28%), Operating profit (+109%), and EBITDA...

David Mudd

Eastroc Beverage A/H Listing - Energized - Fast Growth, Better Margins

Eastroc Beverage Group (605499 CH) (EB), a China-based functional beverage company, aims to raise around US$1bn in its H-share listing. In this...

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Jiangsu Hengrui Pharma A/H Trading - Strong Demand for Quality Asset, but Is Pricey

Jiangsu Hengrui Pharmaceuticals (1276 HK) (JHP, 600276 CH ), a China-based pharmaceutical company, raised around US$1.5bn in its H-share listing....

Sumeet Singh

[Blue Lotus Daily-TMT Update]:NTES US/700 HK/002624 CH/BABA US/PDD US/1357 HK

​NPPA releases May approval results for game licenses; NetEase Games Conference shows progress on 4 new games; EU proposes EUR2 fee on cross-border...

Blue Lotus Research Institute

Xiamen Hithium Pre-IPO: Potential Data Center Play

Xiamen Hithium (XH) is looking to raise at least US$500m in its upcoming HK IPO. It is a potential data-center growth play. In this note, we look...

Nicholas Tan

BABA's Babies: They Are All Grown Up! Ali Pictures: A Blockbuster Company

Ali Pictures reported results exceeding market expectations with growth in Revenue (+33%), Net profit(+28%), Operating profit (+109%), and EBITDA...

David Mudd

Eastroc Beverage A/H Listing - Energized - Fast Growth, Better Margins

Eastroc Beverage Group (605499 CH) (EB), a China-based functional beverage company, aims to raise around US$1bn in its H-share listing. In this...

Sumeet Singh

NPPA releases May approval results for game licenses; NetEase Games Conference shows progress on 4 new games; EU proposes EUR2 fee on cross-border...